Novartis AG’s asthma hopes have been dented somewhat by a Phase III miss for its small molecule candidate QAW039 (fevipiprant). In a note buried in its third-quarter results announcement, the group revealed that the oral product had failed to reach the primary efficacy endpoint of forced expiratory volume (FEV1) improvement in two Phase III trials in patients with moderate asthma. The safety profile was, however, clean.
Novartis’s Fevipiprant Hit By Phase III Asthma Failure
ZEAL Studies Miss Efficacy In Moderate Disease
Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.
More from Respiratory
• By
Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.
• By
A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.
• By
Complete datasets on Tezspire and depemokimab caught the eye at the AAAAI/WAO meeting in San Diego and while the AstraZeneca/Amgen drug appears to be more efficacious, the GSK candidate offers greater convenience.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.